Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma

PLoS One. 2017 Aug 25;12(8):e0183841. doi: 10.1371/journal.pone.0183841. eCollection 2017.

Abstract

Purpose: The objective of this retrospective work was to evaluate the prognostic value on histological response and survival of quantitative indices derived from FDG-PET performed before and after chemotherapy (CHT), in a homogeneous pediatric Ewing sarcoma (EWS) and Osteosarcoma (OST) population.

Methods: Thirty-one patients with EWS and 31 with OST were included. All patients were treated with neoadjuvant CHT, and underwent surgery for local control. All patients had FDG-PET at diagnosis and after CHT, prior to surgery. Several parameters were evaluated: SUVmax, SUVpeak, SUVmean, metabolic tumor volume, total lesion glycolysis, 7 textural features and 3 shape features (SF). The segmentation was performed using an adaptive approach. Results were compared to histopathological regression of the resected tumor and to clinical follow-up for survival evaluation.

Results: For EWS, univariate analysis did not highlight any prognostic value on histological response, or survival regardless of all the considered metrics. For OST, only one of the SF, namely elongation, was significantly associated with PFS and OS on both univariate and multivariate analysis (PFS: p = 0.019, HR = 5.583; OS: p = 0.0062, HR = 7.113).

Conclusion: Only elongation determined on initial FDG-PET has a potential interest as a prognostic factor of PFS and OS in pediatric OST patients. Unlike recent studies of the literature realized in adult population, all the metrics reveal limited additional prognostic value in pediatric EWS patients. This seems to reinforce the question of whether children experience different subtypes of the same pathologies than older patients, with different outcomes.

MeSH terms

  • Adolescent
  • Chemotherapy, Adjuvant
  • Child
  • Female
  • Fluorodeoxyglucose F18 / administration & dosage*
  • Humans
  • Male
  • Neoplasm Metastasis
  • Osteosarcoma / drug therapy*
  • Osteosarcoma / pathology
  • Positron-Emission Tomography / methods*
  • Prognosis
  • Sarcoma, Ewing / drug therapy*
  • Sarcoma, Ewing / pathology
  • Treatment Outcome

Substances

  • Fluorodeoxyglucose F18

Grants and funding

This work was supported by a grant from the French National Agency for Research called “Investissements d’Avenir” no ANR-11-LABX-0018-01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.